BP-009

BP-009 is a preclinical-stage drug candidate being developed by Brillian Pharma for the treatment of epilepsy in children. The product is formulated using Brillian's proprietary "real solution lyophilized" (RSL) technology, which is designed to create stable, ready-to-use or rapidly reconstitutable formulations of drugs that are otherwise difficult to stabilize in liquid form. As a specialty pharmaceutical company focusing on the 505(b)(2) regulatory pathway, Brillian Pharma's BP-009 likely represents an optimized formulation of an existing anti-epileptic agent. The specific active pharmaceutical ingredient (API) and its precise mechanism of action have not been publicly disclosed as of the current preclinical stage.